Compare ROG & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROG | AUPH |
|---|---|---|
| Founded | 1832 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | ROG | AUPH |
|---|---|---|
| Price | $99.74 | $14.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $85.00 | $17.25 |
| AVG Volume (30 Days) | 123.3K | ★ 994.1K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $801,500,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $7.31 | $16.45 |
| P/E Ratio | ★ N/A | $27.00 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $51.43 | $6.55 |
| 52 Week High | $102.29 | $16.54 |
| Indicator | ROG | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 39.81 |
| Support Level | $91.87 | $14.74 |
| Resistance Level | $102.29 | $15.28 |
| Average True Range (ATR) | 2.72 | 0.50 |
| MACD | 0.30 | -0.13 |
| Stochastic Oscillator | 77.79 | 21.87 |
Rogers Corporation designs develop and manufacture engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.